Top Pharmaceutical Stocks To Follow Now – February 05th

Eli Lilly and Company, Merck & Co., Inc., Amgen, Novo Nordisk A/S, and Pfizer are the five Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool. Pharmaceutical stocks refer to shares of companies involved in researching, developing, manufacturing, and selling pharmaceutical products such as drugs, vaccines, and medical devices. Investing in pharmaceutical stocks offers opportunities for investors to potentially benefit from the growth and performance of the healthcare industry. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

LLY traded up $15.21 during trading hours on Wednesday, hitting $841.28. The company’s stock had a trading volume of 2,679,491 shares, compared to its average volume of 3,769,191. The company has a 50-day simple moving average of $785.46 and a 200 day simple moving average of $843.28. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. The firm has a market capitalization of $798.65 billion, a PE ratio of 90.95, a PEG ratio of 1.72 and a beta of 0.42. Eli Lilly and Company has a fifty-two week low of $691.10 and a fifty-two week high of $972.53.

Merck & Co., Inc. (MRK)

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Shares of MRK traded down $0.22 during trading hours on Wednesday, reaching $90.52. 12,210,602 shares of the company’s stock traded hands, compared to its average volume of 12,833,859. Merck & Co., Inc. has a twelve month low of $87.33 and a twelve month high of $134.63. The business’s fifty day simple moving average is $99.58 and its two-hundred day simple moving average is $107.12. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.36 and a quick ratio of 1.15. The firm has a market capitalization of $228.98 billion, a price-to-earnings ratio of 18.96, a P/E/G ratio of 1.20 and a beta of 0.38.

Amgen (AMGN)

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

AMGN traded up $17.24 on Wednesday, reaching $306.26. The company had a trading volume of 3,367,189 shares, compared to its average volume of 3,137,957. Amgen has a one year low of $253.30 and a one year high of $346.85. The company has a market capitalization of $164.62 billion, a P/E ratio of 39.20, a PEG ratio of 2.87 and a beta of 0.56. The company has a fifty day moving average of $271.14 and a 200-day moving average of $303.52. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55.

Novo Nordisk A/S (NVO)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Shares of Novo Nordisk A/S stock traded up $3.69 on Wednesday, hitting $86.31. The company had a trading volume of 10,022,177 shares, compared to its average volume of 9,340,147. Novo Nordisk A/S has a 52 week low of $78.17 and a 52 week high of $148.15. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The company has a market cap of $387.31 billion, a PE ratio of 27.95, a PEG ratio of 0.93 and a beta of 0.45. The business has a 50-day simple moving average of $92.65 and a 200-day simple moving average of $112.19.

Pfizer (PFE)

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

NYSE PFE traded up $0.61 on Wednesday, reaching $26.48. The company’s stock had a trading volume of 27,242,368 shares, compared to its average volume of 37,484,230. The firm’s 50 day moving average is $26.27 and its two-hundred day moving average is $27.79. The stock has a market cap of $150.03 billion, a PE ratio of 35.79, a PEG ratio of 0.66 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer has a twelve month low of $24.48 and a twelve month high of $31.54.